Pacific Biosciences of California
$ 1.47
-6.96%
29 Apr - close price
- Market Cap 490,570,000 USD
- Current Price $ 1.47
- High / Low $ 1.56 / 1.42
- Stock P/E N/A
- Book Value 0.02
- EPS -1.82
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -2.13 %
- 52 Week High 2.73
- 52 Week Low 0.85
About
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
Analyst Target Price
$2.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-13 | 2024-11-07 | 2024-08-07 | 2024-05-09 | 2024-02-15 | 2023-10-30 | 2023-08-02 | 2023-05-02 |
| Reported EPS | -0.12 | -0.12 | -0.13 | -0.15 | -0.2 | -0.17 | -0.64 | -0.29 | -0.31 | -0.26 | -0.28 | -0.36 |
| Estimated EPS | -0.1466 | -0.14 | -0.17 | -0.19 | -0.17 | -0.21 | -0.23 | -0.28 | -0.29 | -0.33 | -0.32 | -0.33 |
| Surprise | 0.0266 | 0.02 | 0.04 | 0.04 | -0.03 | 0.04 | -0.41 | -0.01 | -0.02 | 0.07 | 0.04 | -0.03 |
| Surprise Percentage | 18.1446% | 14.2857% | 23.5294% | 21.0526% | -17.6471% | 19.0476% | -178.2609% | -3.5714% | -6.8966% | 21.2121% | 12.5% | -9.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PACB
2026-04-29 22:15:00
Pacific Biosciences of California (PACB) shares closed down 6.96% at $1.47, underperforming the broader S&P 500. The company is set to report earnings on May 7, 2026, with analysts anticipating an EPS of -$0.17 and revenue of $41 million. Despite the recent dip, the stock has gained 19.7% over the past month, and currently holds a Zacks Rank #3 (Hold).
2026-04-28 00:40:15
Pacific Biosciences of California has updated its SMRT Cell Sequencing 101 guide to reflect the latest advancements in its PacBio HiFi sequencing, including the integration of SPRQ-Nx chemistry. This revision provides an up-to-date view of sequencing capabilities in a single run. The company continues to focus on enhancing high-accuracy genomic analysis tools, previously launching the HiFi sequencing and Vega system for oncology and introducing new solutions for whole genome sequencing and cancer variant detection.
2026-04-27 17:40:15
Pacific Biosciences of California (PACB) recently experienced a significant stock drop, underperforming the general market. This article aims to provide investors with key insights into the company's recent performance and underlying factors. Investors might find this information useful for making informed decisions regarding PACB stock.
2026-04-25 23:10:23
The article discusses why Pacific Biosciences of California (PACB) is outperforming the stock market. It likely delves into factors contributing to its strong performance, such as recent developments, financial results, or market sentiment surrounding the company.
2026-04-24 01:38:53
Pacific Biosciences of California (PacBio) launched its latest SPRQ-Nx chemistry and the Vega system at the PRISM San Diego event. The event featured sessions on cancer and RNA diversity, alongside a Women in Life Science lunch, demonstrating strong community interest in PacBio's technological advancements. PacBio continues to drive innovation in life sciences, building on previous presentations of its HiFi sequencing and Vega system at AACR26 and the introduction of new methods for detecting complex cancer variants.
2026-04-23 21:09:52
Pacific Biosciences (NASDAQ: PACB) will hold its 2026 Annual Meeting of Stockholders virtually on June 3, 2026, where key proposals include electing directors, ratifying Ernst & Young LLP as auditor, approving 2025 executive compensation on an advisory basis, and amending the 2020 Equity Incentive Plan to add 16 million shares. The company highlighted its 2025 financial performance, including $160.0 million in revenue and increased sales of its Revio and Vega systems. Discussions with shareholders influenced compensation practices, with continued emphasis on rigorous performance goals and balanced equity awards to attract and retain talent in a competitive market.
